You are here

  • Home
  • Archive
  • Volume 78, Issue Suppl 2
  • OP0007 HIGH BODY MASS INDEX (BMI) IN PSORIATIC ARTHRITIS (PSA) IS ASSOCIATED WITH HIGHER DISEASE ACTIVITY IN JOINTS AND SKIN, IMPAIRED QUALITY OF LIFE AND MORE DISABILITY: RESULTS FROM THE PSABIO STUDY

Article Text

Article menu

Download PDFPDF

Oral Presentations
WEDNESDAY, 12 JUNE 2019
Comorbidities in psoriatic arthritis
OP0007 HIGH BODY MASS INDEX (BMI) IN PSORIATIC ARTHRITIS (PSA) IS ASSOCIATED WITH HIGHER DISEASE ACTIVITY IN JOINTS AND SKIN, IMPAIRED QUALITY OF LIFE AND MORE DISABILITY: RESULTS FROM THE PSABIO STUDY
Free
  1. Stefan Siebert1,
  2. Paul Bergmans2,
  3. Kurt de Vlam3,
  4. Elisa Gremese4,
  5. Beatriz Joven-Ibáñez5,
  6. Tatiana Korotaeva6,
  7. Wim Noel7,
  8. M.T. Nurmohamed8,9,
  9. Petros Sfikakis10,
  10. Ana Laiz11,
  11. Pavel Smirnov12,
  12. Elke Theander13,
  13. Josef S. Smolen14,
  14. Laure Gossec15,16
  1. 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
  2. 2Biometrics, Janssen-Cilag B.V., Tilburg, Netherlands
  3. 3University Hospitals Leuven, Leuven, Belgium
  4. 4Fondazione Policlinico Gemelli-IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy
  5. 5Hospital 12 de Octubre, Madrid, Spain
  6. 6Nasonova Research Institute of Rheumatology, Moscow, Russian Federation
  7. 7Biometrics, Janssen-Cilag B.V., Brussels, Belgium
  8. 8Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands
  9. 9Amsterdam Rheumatology and Immunology Center | VU Medical Center, Amsterdam, Netherlands
  10. 10University of Athens, First Department of Propaedeutic Internal Medicine and Rheumatology, Athens, Greece
  11. 11Rheumatology, HU. Santa Creu i San Pau, Barcelona, Spain
  12. 12Biometrics, Janssen-Cilag B.V., Moscow, Russian Federation
  13. 13Biometrics, Janssen-Cilag B.V., Lund, Sweden
  14. 14Medical University of Vienna, Vienna, Austria
  15. 15Sorbonne Université, Paris, France
  16. 16Hôpital Pitié-Salpêtrière, Paris, France

Abstract

Background The link between obesity and disease activity in PsA is unclear. Obesity has been associated with a poorer therapeutic response and higher treatment discontinuation rates in patients with PsA being treated with tumour necrosis factor inhibitors (TNFi). Recent data confirm the favourable effect of weight reduction on these factors. There are no data available for other biologics.

Objectives To investigate the relationship between baseline overweight/obesity and disease activity, patient-reported outcomes and disability, in a large real-world cohort of patients with PsA starting biologic treatment with either ustekinumab (UST) or TNFi.

Methods The PsABio study (ClinicalTrials.gov: NCT02627768) is an ongoing observational study evaluating efficacy, tolerability and persistence of 1st, 2nd- and 3rd-line UST or TNFi in PsA in 8 European countries1 when introduced as part of standard clinical care. Baseline data of the study population were collected and analysed for BMI, disease activity (cDAPSA, psoriasis BSA), patient-perceived impact (PsAID-12), disability (HAQ-DI) and presence or history of CVD/MET. Descriptive statistics on available data and 3 exploratory multiple regression models are shown, to investigate the relationship of cDAPSA, PsAID-12 and HAQ-DI (dependent variables) with BMI, adjusted for age, sex, smoking, BSA, CRP, disease duration and biologic treatment.

Results In all, 917 patients were included, starting either UST (n=450) or TNFi (n=467): mean (SD) age 49.7 (12.5) years, 55.5% female. The mean (SD) baseline BMI (N=827) was 28.1 (5.8) kg/m2, with 40.0% and 30.4% in BMI categories overweight (>25–30) and obese (>30), respectively. In univariate analyses, obesity was linked to worse outcomes (Table 1). More severe disease was associated with higher BMI (Table 2). In multiple regression modelling, higher BMI was independently linked to higher cDAPSA (BMI: β=0.09 p=0.026); to higher patient-perceived disease impact measured by PsAID-12 (BMI: β=0.16, p<0.0001) and to higher disability measured by HAQ-DI (BMI: β=0.21, p<0.0001).

Conclusion This multi-country routine-care PsA cohort of patients in need of biologic treatment confirms the high prevalence of overweight/obesity and indicates an independent association between high BMI and disease activity as well as patient-reported impact of disease and disability. These results emphasize the need for lifestyle-directed approaches in PsA, such as overweight management in parallel with joint- and skin-focused treatment.

Figure
Figure

Reference [1] Gossec L, et al. Ann Rheum Dis. 2018;77(Suppl):A1033.

Acknowledgement This study was sponsored by Janssen

Disclosure of Interests Stefan Siebert Grant/research support from: AbbVie, Novartis, Pfizer, Janssen, BMS, Celgene, UCB, and Boehringer Ingelheim, Consultant for: AbbVie, UCB, Pfizer, Janssen, Boehringer Ingelheim, Celgene, and Novartis, Speakers bureau: AbbVie, UCB, Pfizer, Janssen, Boehringer Ingelheim, Celgene, and Novartis, Paul Bergmans Shareholder of: Johnson & Johnson, Employee of: Janssen, Kurt de Vlam Consultant for: Pfizer Inc, Consultant for: Johnson & Johnson, Elisa Gremese Consultant for: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Sanofi, UCB, Roche, and Pfizer, Speakers bureau: BMS, Speakers bureau: Roche, Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Sanofi, UCB, Roche, and Pfizer, Beatriz Joven-Ibáñez Speakers bureau: Celgene, Novartis, MSD, Pfizer, AbbVie, and Janssen, Tatiana Korotaeva Consultant for: Pfizer, MSD, Novartis, AbbVie, Celgene, Biocad, Janssen, UCB, Lilly and Novartis-Sandoz, Speakers bureau: Pfizer, MSD, Novartis, AbbVie, Celgene, Biocad, Janssen, UCB, Lilly and Novartis-Sandoz, Wim Noel Employee of: Janssen, M.T. Nurmohamed Grant/research support from: Pfizer, AbbVie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Lilly, Sanofi, and Celgene., Grant/research support from: Pfizer, Abbvie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Eli Lilly, Celgene & Sanofi, Consultant for: Pfizer, AbbVie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Lilly, Sanofi, and Celgene., Speakers bureau: Pfizer, AbbVie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Lilly, Sanofi, and Celgene., Speakers bureau: Pfizer, Abbvie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Eli Lilly, Celgene & Sanofi, Petros Sfikakis: None declared, Ana Laiz Consultant for: Lilly, Novartis, AbbVvie, MSD, UCB and Janssen, Speakers bureau: Lilly, Novartis, Abvvie, MSD, UCB and Janssen, Pavel Smirnov Employee of: Janssen, Elke Theander Employee of: Janssen, Josef S. Smolen Grant/research support from: AbbVie, Eli Lilly, Janssen, MSD, Pfizer Inc, Roche, Consultant for: AbbVie, Amgen, AstraZeneca, Astro, Celgene, Celtrion, Eli Lilly, GlaxoSmithKline, ILTOO, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer Inc, Roche, Samsung, Sanofi, UCB, Speakers bureau: AbbVie, Amgen, AstraZeneca, Astro, Celgene, Celtrion, Eli Lilly, GlaxoSmithKline, ILTOO, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer Inc, Roche, Samsung, Sanofi, UCB, Laure Gossec Grant/research support from: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Sanofi, and UCB, Consultant for: AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, MSD, Nordic Pharma, Novartis-Sandoz, Pfizer, Roche, Sanofi, and UCB, Consultant for: L Gossec has received honoraria from Celgene as investigator for this study

http://dx.doi.org/10.1136/annrheumdis-2019-eular.5841

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.